The global "AI in drug discovery" market is expected to expand by a CAGR of 30% between now and 2030 and lead to approximately 50 novel therapies being brought to market over the next decade, with annual sales in excess of $50 billion.

This article highlights the performances last week and MTD of the 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies along with their areas of focus in our Clinical-Stage BioTech Drug Stocks Portfolio.

The drug development process is very expensive and time-consuming which creates a huge shortage in drug candidates and programs but the advent of AI can significantly shorten and cheapen this process and this is already happening.

This article highlights the performance last week of the 10 clinical-stage AI-powered and psychedelic compound-based drug discovery companies in the munKNEE Clinical-Stage BioTech Drug Stocks Portfolio,

A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and MTD, and their areas of focus.